Mineralys Therapeutics, Inc. Common Stock (MLYS) Stock Price
MLYSStock
$25.60+68.20%52W
Market Cap$2.26B
P/E—
PEG Ratio—
Div yield—
Beta0.60
MLYS Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-26.48%
Price vs S&P 500 (4W)-2.24%
VGM Score54.54
MLYS Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q2 2026 | -$0.54 | -$2.85 | -432.71%(-$2.32) | |
| Q1 2026 | -$0.44 | -$0.47 | -6.82%(-$0.03) | |
| Q4 2025 | -$0.52 | -$0.40 | +22.52%(+$0.12) | |
| Q3 2025 | -$0.61 | -$0.52 | +15.15%(+$0.09) | |
| Q2 2025 | -$0.74 | -$0.66 | +10.64%(+$0.08) |
MLYS Analyst Recommendations
May 2026
Jun 2026
Jul 2026
Aug 2026
4.19
4.19
4.19
4.19
Industry Peers — Pharmaceuticals(570)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
MLYSMineralys Therapeutics, Inc. Common Stock | — | — | C | $25.60 |
| LLYEli Lilly & Co. | D | B | C | $1174.61 |
| JNJJohnson & Johnson | D | C | B | $268.04 |
| ABBVABBVIE INC. | D | C | B | $255.48 |
| MRKMerck & Co., Inc. | D | C | B | $148.35 |
| NVSNovartis AG | C | C | C | $153.81 |
| AZNAstraZeneca PLC | C | B | C | $162.70 |
| NVONovo-Nordisk A/S | B | C | C | $45.61 |
| ABTAbbott Laboratories | C | C | C | $112.47 |
| PFEPfizer Inc. | C | D | B | $27.96 |
| VRTXVertex Pharmaceuticals Inc | D | C | B | $541.69 |
About Mineralys Therapeutics, Inc. Common Stock
Mineralys Therapeutics is a clinical-stage biopharmaceutical company developing lorundrostat, a selective aldosterone synthase inhibitor for treatment-resistant hypertension. The orally administered drug targets abnormally elevated aldosterone levels in patients who have not responded to multiple existing antihypertensive therapies.